Insomnia, restless leg syndrome, sleep apnea, and other sleep issues often affect quality of life in cancer patients, their caregivers, and survivors. Unfortunately, sleep complaints can often be overlooked by the medical staff or not mentioned by the patient.
The concerns a family might have when a loved one develops squamous cell carcinoma of the oral cavity might seem obvious: fear that the patient will have a shorter life due to advanced disease, empathy for her pain, and a feeling of isolation in facing a rare presentation of cancer.
Imagine a woman with a weight problem who, two weeks after chemotherapy, goes to her doctor with a urinary tract infection and a rash on her upper chest.
While clinical trials remain a treatment option and play a significant role in furthering cancer research in treatment, symptom management and survivorship, less than 5 percent of patients participate in them, and 40 percent of patients report that they do not understand the idea of a clinical trial.
When former president Richard Nixon signed the National Cancer Act in 1971, survivorship care was not even a topic of discussion due to extensive inpatient care and high mortality rates from the disease.
While surgical advances and new treatment approvals, including Lynparza and Avastin, have improved the outlook in ovarian cancer, late diagnosis and tumor resistance remain as significant barriers to major progress in treating the disease.
Expecting to live is more pleasant than expecting to die.
In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 22-1 to recommend approval of T-VEC.
The FDA has assigned a priority review designation to Opdivo (nivolumab) as a treatment for previously untreated patients with unresectable or metastatic melanoma.
It's one thing to know you have to get a certain treatment, it's another thing entirely to wait for it to come.
A breast cancer and melanoma survivor shares her perspective on living with "wait and watch."
The efficacy of Imbruvica (ibrutinib) and Zydelig (idelalisib) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients.
In two weeks, I will be at Mayo Clinic undergoing my annual screening for the various Lynch syndrome-related cancers for which I am at risk.
A recent study enrolled 1,589 black women and 1,256 white women who underwent screening mammography at the University of Pennsylvania from 2010 to 2011.
It's easy to feel alone dealing with cancer. Being a part of a social media community that "gets it" can be invaluable to healing.
I feel hurt and sad that my father is not there for me. I need to focus on and cherish my family of the heart.
Each year for the past nine years, CURE has hosted an event at the Oncology Nursing Society Annual Congress that honors oncology nursing.
In a moving ceremony that drew tears from many in a crowd of nearly 1000, one outstanding nurse was recognized last night with CURE magazine's 2015 Extraordinary Healer Award for Oncology Nursing.
The FDA has approved second-line Cyramza in combination with FOLFIRI chemotherapy regimen as a treatment for patients with metastatic colorectal cancer following progression on a first-line Avastin-containing regimen.
These are the powerful and immediate benefits of yoga designed for cancer patients: their empowerment to help themselves gain some control over anxiety, a restless mind, and the whirlwind of change that comes with a cancer diagnosis.
A guide for allogeneic transplant patients after the hospital.
Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma.
Frontline immunotherapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) delayed disease progression by 60 percent compared with Yervoy alone in patients with advanced melanoma.
Everyone's chemotherapy experience is unique.
The FDA has granted a priority review to the antibody-drug conjugate Adcetris as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression.
The Food and Drug Administration has granted a breakthrough therapy designation to Xalkori (crizotinib) as a potential treatment for patients with ROS1-positive non–small cell lung cancer, based on phase 1 findings published in the New England Journal of Medicine.
A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Keytruda (pembrolizumab) had an overall response rate (ORR) of 45.2 percent among a cohort of patients with high PD-L1-expressing non–small cell lung cancer in the early phase KEYNOTE-001 trial.
Planning a flight on a domestic or international airline? If you have active cancer, do your homework first.
MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.
